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Macrophages, the final effector cells in many cellular immune responses, are
able to destroy a variety of intracellular pathogens, such as viruses, fungi,
chlamydia, rickettsiae, and leishmania (1, 2), as well as neoplastic cells (3). It has
been demonstrated that human monocyte-derived macrophages can be activated
by conditioned medium from lectin-stimulated human peripheral blood lympho-
cytes to kill Leishmania donovani (4), and the substanceresponsible forthisactivity
has been shown to be IFN-y (5).
However, several macrophage-activating factors distinct from IFN-y have been
detected (6-15). Themolecular cloning ofmonokinesandlymphokines including
human granulocyte/macrophage colony-stimulating factor (GM-CSF)' (16)
makes it possible to test these homogeneous factors for their capacity to activate
macrophages.
Colony-stimulating factors are defined by their capacity to stimulate the clonal
expansion of individual progenitor cells resulting in the generation of distinct
colonies (17), which in the case of GM-CSF consist of granulocytes and macro-
phages (18). Recombinant GM-CSF (rGM-CSF) was found to have all the effects
on human bone marrow cells of GM-CSF produced by T cells (16), to alter the
physiology of mature neutrophils (19) and eosinophils (20), and to activate
macrophages for extracellular killing oftumor cells (21).
The data reported here show that rGM-CSF, which shares no sequence
homologywith IFN-y (16), isalso a potent activator ofcultured human monocyte-
derived macrophages and induces the intracellular killing of L. donovani. The
antileishmanial effect of both rGM-CSF and IFN-y does not depend on LPS as
an additional signal . However, unlike rIFN-y, which requires 48-72 h to activate
macrophages to kill L. donovani, the antileishmanial effect ofrGM-CSF is sooner
and reaches maximal activation at 36 h.
This work wassupported by grants AI-22801, T32 AI-07061,AI-22532, AI-22530, CA-41063, and
AM-35907 from the National Institutes of Health.
'Abbreviationused in this paper:
￿
GM-CSF, granulocyte/macrophage colony-stimulating factor.
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Materials and Methods
Parasites.
￿
Promastigotes of L. donovani were obtained from the World Health Orga-
nization, Geneva, Switzerland, and were maintained in vitro at 26°C in tissue culture
flasks containing Schneiders's Drosophila medium (Gibco Laboratories, Grand Island,
NY), 20% heat-inactivated FCS, and 5 ng/ml gentamycin (M.A. Bioproducts, Walkersville,
MD). The parasites were subcultured by weekly passage at 1 :10 dilution. To obtain
amastigotes of L. donovani, 10' promastigotes were injected via the intracardiac route to
hamsters. Spleen from infected animals were removed ^-8 wk after infection. Amastigotes
were isolated from homogenates of infected spleens according to the method of Chang
and Hendricks (22) using Percoll gradient centrifugation.
Cells.
￿
Human peripheral blood was obtained from healthy volunteers. Mononuclear
cells isolated by Ficoll-Hypaque density centrifugation were suspended at 2.5 x 106
cells/ml in medium 199 (M.A. Bioproducts) containing 15% heat-inactivated FCS, 2 mM
r.-glutamine (Gibco Laboratories), and 5 ng/ml gentamycin, and seeded on top of four
glass coverslips in a 35-mm petri dish (Falcon Labware, Oxnard, CA). All the FCS used
for the study was from the same lot (No. 11 N5261), which was prescreened and selected
from many lots for the ability to support in vitro culture of cells and parasites. After 2 h
ofincubation at 37'C the nonadherent cellswere removed by washing, and the remaining
cells were incubated for 10-12 d in a 5% C02 atmosphere to obtain monocyte-derived
macrophages. The cultures were examined every3-4 d and the culture medium described
above was replenished at the same time. Only monolayers containing cells with marked
increase in size and cytoplasmic spreading were chosen as effector cells for experiments,
whereas cultures containing poorly differentiated cells were discarded. After 10 d, the
monolayers consisted of95-97% macrophages, as determined by morphologyand esterase
staining.
In experiments where LPS-free condition was required, extreme caution was taken to
ensure the absence of LPS . Human mononuclear cells were processed in solutions and
medium prepared with LPS-free water (Travenol Laboratories, Inc., Deerfield, IL) and
cultured in LPS-free medium supplemented with 15% autologous serum. The absence of
LPS of all cultures was ensured before use by monitoring LPS at each step with the
Limulus Amebocyte Lysate Assay (M.A. Bioproducts). Both rGM-CSF and IFN-y were
also examined for the presence of LPS before use. Occasionally, 0.3-0.5 ng/ml of LPS
was found in rIFN-f preparations; therefore, a stock of IFN-,y (Meloy Laboratories, Inc.,
McLean, VA) free of detectable (<0.01 ng/ml) was used in LPS-free studies.
Recombinant Human GM-CSF and Recombinant Human IFN--y.
￿
rGM-CSF, isolated by
COS cell expression screening of cDNA from Mo cells for GM-CSF activity using KG-1
human myeloid leukemia cells and fresh human bone marrow cells (16), was provided by
Genetics Institute, Cambridge, MA. The specific activity of purified rGM-CSF was 10'
U/mg protein, whereas the titer of crude rGM-CSF was 80,000 U/ml. Crude GM-CSF
was used for most of one study, unless indicated otherwise. Crude rIFN-,y was also
provided by Genetics Institute. The titer of rIFN-,y was 106 U/ml. Various dilutions of
rGM-CSF or rIFN-,y were added to monocyte-derived macrophage preparations after the
cells had been in culture for 10-12 d.
Infection ofMonocyte-derived Macrophages.
￿
Promastigotes of L. donovani at the station-
ary growth phase were used to infect macrophages at parasite-to-cell ratio of -10:1 in all
experiments. In experiments using amastigotes, freshly isolated amastigotes were used to
infect macrophages at a ratio of ^-8:1 . After 2 h of incubation at 37'C, the uningested
parasites were removed by washing, and the cultures were reincubated in fresh medium.
Coverslips were removed at 2, 24, 48, and 72 h, washed in PBS, and stained with Diff-
Quick stain (American Scientific Products, McGaw Park, IL); the number of intracellular
parasites was determined by microscopy. From each coverslip, three to four randomly
selected areas were examined; each area consisted of 100 cells.1438
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FIGURE 1 .
￿
The effect of rGM-CSF and rIFN-y on the
intracellular fate of L. donovani in human monocyte-
derived macrophages. The monocyte-derived macro-
phages were treated with rGM-CSF, 4 ng/ml (0) or rIFN-
y, 1,000 U/ml (O), or received only fresh medium (con-
trol, 0) for 72 h before infection with L. donovani. After
2 h of incubation at 37°C,the uningested parasites were
removed by washing and the cultures were reincubated
in fresh medium containing no rGM-CSF or rIFN-y.
Coverslips were removed at 2, 24, 48 and 72 h, washed,
and stained. The number of intracellular parasites was
determined by microscopy. The starred circle represents
the overlaps of open circle, closed circle, and diamond.
Three experiments are shown; each is expressed as the
mean ± SEM of threequantifications.
Results
Killing of Intracellular Leishmania Donovani by rGM-CSF or rIFN-y-activated
Monocyte-derived Macrophages. It hasbeen shown that I-d-old human monocytes
displayed effective promastigocidal activity and eradicated >90% of ingested
parasites 24 h after infection (4). However, monocyte-derived macrophages
(monocytes cultured for >7 d) that could be activated to exhibit antileishmanial
activity, displayed little or no leishmanicidal activity towards promastigotes of L.
donovani and none towards amastigotes. Instead, these cells readily supported
the replication of both parasite forms. Therefore, monocyte-derived macro-
phages were used as the effector cells in the present study. IFN-y has been shown
to activate human mononuclear phagocytes cultured for 10-20 d to kill intra-
cellular L. donovani (5), with optimal results being achieved after 48-72 h of
exposure. To determine ifrGM-CSF can activate macrophages for antileishman-
ial activity and to compare the effect of pretreatment with rGM-CSF or rIFN-y
on cultured monocyte-derived macrophages, rGM-CSF (4 ng/ml, the optimal
dose) or rIFN-y (1,000 U/ml) was added once to 10-d-old cultures of monocyte-
derived macrophages for 72 h before infection with the parasites. The actual
replication of the parasites in rGM-CSF- and rIFN-7-treated cultures was com-
pared with cultures receiving medium alone.
As can be seen in Fig. 1, the uptake ofparasites after 2 h was similar for each
group, indicating no differential uptake ofparasites among lymphokine-treated
cells. In the control cultures, monocyte-derived macrophages readily supported
the replication of L. donovani. However, in macrophages pretreated with rGM-
CSF or rIFN-7, the growth of the parasites was inhibited.
We initiated our studies of the Leishmania-macrophage interaction using the
promastigote because the hemoflagellate is the form first encountered by the
phagocytic cells. The amastigote, however, to which the promastigote rapidly
transforms within the phagolysosomes, is responsible for persistent tissue infec-WEISER ET AL.
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TABLE I
Enhancement ofAntileishmanial Activity by rGM-CSF and rIFN-'y
* Monocyte-derived macrophages were pretreated with rGM-CSF(4 ng/ml) or rIFN-'Y (1,000 U/ml)
for 72 h. The cells were then infected with amastigotes of L. donovani. Coverslips from treated
cultures and control cultures (cultures received no lymphokine) were removedat 2, 24, 48,and72
h after infection and were stained.
$ Thenumber of intracellular amastigotes present in lymphokine-treated as well as control cultures
at each time pointwasdetermined by counting the respective number ofparasites in four randomly
selected areas (each areasconsisted of 100 macrophages) of every coverslip andexpressedas mean
± SEM of four countings. All the experiments within each group were analyzed together by the
two-way analysis of variance. Statistically significant increase in antileishmanial activity was found
in cultures treated with GM-CSF as well as IFN-y (p < 0.1).
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tion. Therefore, amastigotes were also used to infect monocyte-derived macro-
phages treated with rGM-CSF or rIFN-y. The antileishmanial effect ofthese two
lymphokines was evaluated (Table 1). Again, there was a significant decrease of
amastigotes in macrophages treated with either lymphokine, although the anti-
leishmanial effect was more pronounced when promastigotes were used.
The Fig. 2 shows the antileishmanial effect of increasing concentrations of
purified rGM-CSF on monocyte-derived macrophages infected with L. donovani.
Killing of L. donovani was observed at a concentration as low as 0.5 ng/ml rGM-
CSF, and the optimal effect was reached at 4 ng/ml. The antileishmanial effect
of rGM-CSF was entirely abolished by treatment of rGM-CSF with anti-rGM-
CSF antiserum but not with anti-rIFN-y mAb (Fig. 3). However, it is of note
that no antileishmanial activity was observed in monocyte-derived macrophages
treated with human recombinant macrophage-colony stimulating factor (ob-
Time
Number of amastigotes per 100 macrophages
after in- Control rGM-CSF (4 ng/ml) rIFN-y (1,000 U/ml)
fection*
h
Exp. I Exp. 2 Exp. I Exp. 2 Exp. I Exp. 2
2 173±10 217±15 186±20 220±17 166±5 213±8
24 181±12 233±16 167±11 219±9 161±14 212±14
48 240 ± 18 276 ± 19 175 ± 8 199 ± 13 156 ± 13 168 ± 21
72 377 ± 20 496 ± 24 249 ± 18 352 ± 19 200 ± 16 253 ± 161440
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FIGURE 3.
￿
Effect ofanti-rGM-CSF oranti-IFN-y an-
tibody on the antileishmanial activity of rGM-CSF.
rGM-CSF (4 ng/ml) was incubated with protein A-
Sepharose-bound sheep anti-human rGM-CSF anti-
serum (40 ng/ml) or with protein A-Sepharose-
bound anti-IFN-y mAb (4,000 neutralizing units/ml)
overnight at 4°C. The slurry was removed by centri-
fugation at 300gfor 10 min. 4 ng/ml rGM-CSF (p),
rGM-CSF treated with anti-rGM-CSF antibody (0), or
rGM-CSF with anti-IFN-y antibody (/)were added to
cultured macrophages 72 h before infection with L.
donovani. The percentage of parasites killed was as-
sessed 48 hafter infection andcalculated as described
in Table I. Three experiments are shown; each is
expressedas themean tSEMofthreequantifications.
tained from Genetics Institute), another cytokine produced by using the same
COS cell expression system as rGM-CSF (data not shown).
It has been reported that the macrophage-activating activity of IFN-7 is
dependent on the presence of small amounts of bacterial LPS as a second signal
(21, 23, 24). Therefore, to assess whether exogenous LPS is required for
antileishmanial activity of rGM-CSF or IFN-1', human monocyte-derived mac-
rophages were processed and cultured under stringent LPS-free conditions as
describedin Materialsand Methods. rGM-CSF and IFN-7, both free ofdetectable
amounts of LPS, were used to activate monocyte-derived macrophages with and
without the addition of 10 ng or 50 ng/ml of LPS. As illustrated in Table II, the
antileishmanial activity of both rGM-CSFand IFN-'y was found not to be affected
by the addition of either 10 ng or 50 ng of LPS. Furthermore, both lymphokines
were able to function in a LPS-free environment since culture medium removed
at the termination of the experiment (72 h after infection) contained no detect-
able amount of LPS (<0.01 ng/ml). In addition, LPS alone showed no antileish-
manial activity.
Time Course of rGM-CSF.
￿
The antileishmanial effect of pretreating cultured
monocyte-derived macrophages for different times with 4 ng/ml rGM-CSF or
with 1,000 U/ml rIFN-7 was measured 48 h after infection (Fig. 4). Already at
6 h of pretreatment, activation was seen with rGM-CSF, whereas no effect was
seen with rIFN-.y. Optimal activation with rGM-CSF occurred at 36 h of pre-
treatment with rGM-CSF whereas activation by rIFN-y was maximal only after
72 h of preincubation. The latter is in agreement with previous reports by
Murray and Cartelli (4). These studies clearly demonstrate that rGM-CSF acti-
vates cultured human monocytes quicker than rIFN-gamma.
Are the Antileishmanial Effects of rGM-CSF and rIFN-y Additive?
￿
Our experi-
ments show that even when optimal concentrations of rIFN-y or rGM-CSF are
used, all intracellularparasites are not eradicated. Some residual parasites remain
insensitive to the treatment of macrophages with either lymphokine. These
observations bringup the question: can the residual parasite population be killed
by treating monocyte-derived macrophages with a combination of rGM-CSF and
rIFN-y, especially in view of the reports that IFN-y but not GM-CSF inducedTABLE II
Failure ofLPS to Alter Macrophage Antileishmanial Activity Induced by GM-CSF and IFN-y
* Monocyte-derived macrophges were treated as indicated above for 72 h. The cells were then
infected with promastigotes of L. donovani for 2 h. Coverslips were removedat 2 h and 48 h after
infection.
$ The number of intracellular parasites per 100 macrophages at 2 h and at 48 h after infection was
determined as described in Table I. All the experiments within each group were analyzed by the
two-wayanalysis of variance. No statistical significance wasfound to reject the null hypothesis of
equal activity ofactivatedsamplesuntreatedor further treated with LPS. Therefore, it is concluded
that no significant enhancement ofactivity is detected by adding LPS to GM-CSF or IFN-y-treated
cultures.
WEISER ET AL.
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Treatment*
Number of parasites/100 macrophages*
At 2 h At 48 h
Exp. I Exp. 2 Exp. I Exp. 2
None 188 ± 14 134 ± 11 551 t 40 473 t 34
GM-CSF
0.5 ng/ml 178 t 7 150 ± 10 457 t 44 383 t 23
0.5 ng/ml + 10 ng/ml LPS 191 t 21 124 f 9 446 t 38 388 t 37
0.5 ng/ml + 50 ng/ml LPS 169t 15 127 t 12 455 t 27 355 f 27
4 ng/ml 181 t 16 149 t 13 209 t 43 194 t 32
4 ng/ml + 10 ng/ml LPS 195 t 21 144 t 8 193 t 49 208 t 14
4 ng/ml + 50 ng/ml LPS 166 t 17 132 t 17 253 t 32 213 t 38
IFN-y
1,000 U/ml 176 ± 13 128 t 14 248 t 51 241 t 29
1,000 U/ml + 10 ng/ml LPS 183 ± 15 151 t 9 276 t 39 232 t 34
1,000 U/ml + 50 ng/ml LPS 162t 14 119 t 11 231 t 24 222 t 22
LPS, 10 ng/ml 201 t 13 143 t 18 529 t 29 485 t 51
LPS, 50 ng/ml 177± 14 129 t 11 583 t 41 462 t 28
FIGURE 4. The antileishmanial effect
of pretreatment time with rGM-CSF or
rIFN-y on the cultured macrophages.
W 600 The abscissa shows the pretreatment
time.Theordinate showsthe number of
parasites per 100 macrophages assessed
48 h afterinfection. rGM-CSF, 4 ng/ml
400 (9) and rIFN-y, 1,000 U/ml (0) were
used. The data are expressed as mean of
w threeexperiments t SEM. The data de- y rived from cultures treated with GM-
CSF or IFN-y at each time point were
analyzed by theanalysis ofvariance. The
a p values for the time points presented
are as follows: 6 h, p < 0.005; 12 h, p<
0.005;24 h, p <0.025;48 h, p= 0.025;
12 24 49 72 72 h, p < 0.25. As evidenced by the p
values, there exists statistically signifi-
PRETREATMENT TIME (HOURS) cant difference betweenpretreatment of
monocyte-derived macrophages with
GM-CSF and IFN-yat 6, 12, 24,and48
h, but not as 72 h.1442
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FIGURE 5. Antileishmanial activity of combined
treatment of monocyte-derived macrophages with
rGM-CSF and rIFN-y. Cells were treated with me-
diumalone (0), 200U/ml rIFN-y (A), 0.5 ng/ml rGM-
CSF (A), 0.5 ng rGM-CSFand 200 U/ml rIFN-y (*),
1,000 U/ml rIFN-y (0), 4 ng/ml rGM-CSF (9), or 4
ng/mlrGM-CSFand 1,000 U/ml rIFN-y (*)for 72 h
before infection with L. donovani. Number of intra-
cellular parasites were was 2, 24, 48, and 72 h after
infection. The data represent the mean of three ex-
periments.
human macrophages to secrete H202 (25) and that promastigotes of L. donovani
were found to be exquisitely susceptible to H202 (4). Results of three separate
experiments using different concentrations of rGM-CSF and rIFN-y concomi-
tantly are shown in Fig. 5 . As can be seen, pretreatment of monocyte-derived
macrophages with a combination of rGM-CSF and rIFN-y at suboptimal doses
(0.5 ng/ml and 200 U/ml) results in an additive killing effect of L. donovani,
when compared with pretreatment with either lymphokine alone. However,
pretreatment with rGM-CSF and rIFN-y at optimal doses (4 ng/ml and 1,000
U/ml) showed no significant enhanced killing of parasites.
Discussion
These results demonstrate that human rGM-CSF activates cultured human
monocyte-derived macrophages to exhibit antileishmanial activity towards both
promastigotes and amastigotes ofL. donovani. The activation ofthe macrophages
by rGM-CSF is maximal after 36 h of incubation, whereas, activation by rIFN-y
is maximal at 72 h. The activation of intracellular killing by rGM-CSF or by
IFN-y does not require LPS as a second stimulus; the antileishmanial effect of
both lymphokines containing no detectable LPS is not potentiated by the addition
of LPS. Furthermore, treatment with LPS alone showed no effect on the
intracellular killing of L. donovani. In this context, Grabstein et al. (21) found
that the capacity of GM-CSF to activate macrophages to lyse A375 target cells
was independent ofstimulation with suboptimal amountsof LPS, but the capacity
of IFN-y to activate macrophages, on either hand, required the addition of
suboptimal amounts of LPS to achieve lysis of the same cells. Furthermore, LPS
alone (1 ng or 10 ng/ml) was able to induce nonspecific tumoricidal activity.
Other studies have also addressed the process of macrophage activation by
GM-CSF. In regard to antileishmanial activity, it was demonstrated that condi-
tioned medium from mouse spleen cells containing GM-CSF activity was able to
enhance ingestion and killing of Leishmania tropica by mouse macrophages (26);WEISER ET AL.
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however, in this study homogeneity of GM-CSF could not be demonstrated in
order to exclude the action of IFN-y. On the other hand, Ralph et al. (27) also
using conditioned medium from mouse spleen cells reported that GM-CSF
obtained by gel chromatography of conditioned medium does not play a role in
the induction of tumoricidal and microbicidal activity of mouse macrophages.
The reason for the latter finding could be the presence of an inhibitor of GM-
CSF in the conditioned medium or insufficient pretreatment time of macro-
phages, or that mouse GM-CSF indeed lacks macrophage-activating activity . The
antimicrobial activity of GM-CSF has recently been extended to Trypanosoma
cruzi and Salmonella typhimurium (13, 15). In these studies, treatment of rGM-
CSF was found to activate human peripheral blood monocytes and macrophages
as well as mouse peritoneal macrophages for the inhibition of intracellular
replication of trypomastigotes of T. cruzi (13, 15), and daily GM-CSF therapy
significantly increased the survival of mice challenged with a lethal dose of S.
typhimurium (13).
Recently, the contribution ofhighly active NK cells, which are present in small
numbers in monocyte preparations, to extracellular cytotoxicity has gained
increasing attention (28). This is important because target cells, including the
A375 cell line, previously thought to be exclusively sensitive to monocyte killing
were found to be highly susceptible to NK cell killing. We have circumvented
this problem by assessing intracellular killing associated exclusively with macro-
phages.
It is not yet clear how GM-CSF induces antileishmanial activity in macrophages
upon infection with leishmania. Human mononuclear phagocytes have been
shown to use both oxygen-dependent and -independent mechanisms to kill
ingested Leishmania (4). In the oxygen-dependent mechanism, H202 has been
identified as the key leishmanicidal oxygen intermediate (29, 30). Whereas IFN-
y has the capability to induce mononuclear phagocytes to use both oxygen-
dependent and -independent mechanisms to achieve leishmanicidal activity (4),
GM-CSF, on the other hand, did not enhance H202 release from macrophages
upon triggering with PMA (25). However, it is not entirely impossible that
macrophagestreated with GM-CSFare rendered moresusceptible to betriggered
for oxidative burst during parasite entry than untreated macrophages, since
oxidative burst could also be readily triggered by the entry ofpromastigotes of
L. donovani (4). Alternatively, GM-CSF might operate through an oxygen-
independent mechanism to achieve antileishmanial activity. In a recent report
by Passwell et al. (31), mAbto IFN-y, which abrogated theincrease in production
of H202 induced by supernatants from mitogen-stimulated human peripheral
blood mononuclear cells, resulted in only partial inhibition of leishmanicidal
capacity of these lymphokines on human monocytes. It is also possible that GM-
CSF activates macrophages to release TNF and that some ofthe biological effects
of GM-CSF might be amplified through the release of TNF. By Nothern blot
analysis, rGM-CSF has recently been shown to induce expression of the TNF
gene in U937 cells and in normal human monocytes (32). Furthermore, rGM-
CSF, but not rIFN-y was found to induce human monocyte-derived macrophages
to express mRNA for TNF-a (33). Also, rTNF has been demonstrated to inhibit
intracellular multiplication oftrypomastigotes ofT. cruzi in murine macrophages1444
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(10). The role of TNF in the antileishmanial action is currently being investi-
gated.
The experiments reported here show that homogeneous human rGM-CSF
devoid of other lymphokines induces intracellular killing of L. donovani by
monocyte-derived macrophages. The role ofGM-CSF in vivo as a macrophage-
activating factor and its functional relationship to IFN-y remains to be deter-
mined. GM-CSF might be produced rapidly after an antigenic stimulus, or
exposure to endotoxin or IL-1, because injection of various Salmonella antigens
or endotoxin into mice caused a 50-100-fold increase of serum CSF levels,
maximal at 3-9 h (34), and administration of 100 ng of human IL-1 to mice
resulted in the appearance of high serum titers of CSF at 3 and 6 h (35).
Therefore, GM-CSF might be important whenever early activation of macro-
phages is necessary, whereas IFN-y might function as a long-term macrophage-
activating factor. Since simultaneous administration ofsuboptimal doses ofrGM-
CSF and rIFN-y to macrophages induces an additive antileishmanial effect, it
may be beneficial to combine these two lymphokines therapeutically to promote
hematopoietic cell proliferation and to activate macrophages.
Summary
Recombinant granulocyte/macrophage colony-stimulating factor (rGM-CSF)
obtained from cloned complementary Mo cell DNA and expressed in COS-1
cells activates cultured peripheral blood monocyte-derived macrophages in vitro
to become cytotoxic for intracellular L. donovani. The antileishmanial effect of
rGM-CSF, which can be completely neutralized by anti-rGM-CSF antiserum, is
maximal after 36 h preincubation with the cultured macrophages, compared
with that ofrIFN-gamma, which reaches its maximum at 72 h ofpreincubation.
The antileishmanial effect of GM-CSF as well as IFN-y is independent of
detectable amounts of LPS and is not augmented by the addition of 10 or 50
ng/ml of LPS. Simultaneous administration of suboptimal doses of rGM-CSF
and rIFN-y to monocyte-derived macrophages results in greater antileishmanial
activity by these cells than administration of either lymphokine alone, although
no enhancement of antileishmanial activity is observed when optimal doses of
these two lymphokines are applied together.
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